ERBB2 and cancer: The use of ICIs in monotherapy regimen or combined to HER2-blocking agents, anthracyclines, VEGF inhibitors, CDK6 inhibitors, and hormonal therapies creates a synergistic risk for cardiorenal toxicity in cancer patients.